Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7653496 | 0.86 | MEN1 (0.53) | MEN1NPC1RAB9AKMT2ACTSS | |
| SCHEMBL6358461 | 0.81 | TAS1R3 (0.42) | CTSSCHRNA7OPRM1OPRK1OPRL1 | |
| SCHEMBL7546031 | 0.74 | NPC1 (0.60) | MEN1NPC1RAB9AKMT2ACYP3A4 | |
| SCHEMBL7007596 | 0.64 | RORC (0.46) | NPC1RAB9ATMPRSS2 | |
| SCHEMBL27979643 | 0.64 | MEN1 (0.84) | MEN1NPC1RAB9AKMT2ACYP3A4 | |
| SCHEMBL17512426 | 0.64 | RAB9A (0.61) | MEN1NPC1RAB9AKMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL7847628 | 0.64 | RORC (0.45) | NPC1RAB9ATMPRSS2 | |
| SCHEMBL501922 | 0.64 | NPC1 (0.73) | MEN1NPC1RAB9AKMT2ACYP3A4 | |
| SCHEMBL25574382 | 0.63 | GPR142 (0.63) | MEN1NPC1RAB9AKMT2ACYP3A4 | |
| SCHEMBL25574371 | 0.63 | GPR142 (0.58) | MEN1NPC1RAB9AKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874625-B1 | INDANE DERIVATIVES FOR ANTIPSYCHOTIC COMPOSITIONS | LILLY CO ELI (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1003495-A4 | PHARMACEUTICAL COMPOUNDS | LILLY CO ELI (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6429317-B1 | MUSCARINIC RECEPTOR MODULATORS; CENTRAL NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS; SCHIZOPHRENIA | ELI LILLY AND COMPANY | 2002-08-06 | — | — | US | disclosed |
| US-6395735-B2 | AN INDANE-LIKE COMPOUNDS WHICH CAN BE USEFUL FOR TREATING PSYCHOSIS AND OTHER CONDITIONS ASSOCIATED WITH MODULATION OF A MUSCARINIC RECEPTOR | ELI LILLY AND COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-20010012848-A1 | Pharmaceutical compounds | HOLLINSHEAD SEAN PATRICK (US) | 2001-08-09 | — | — | US | disclosed |
| US-6211364-B1 | PSYCHOLOGICAL DISORDERS; ALZHEIMER'S DISEASE; CROHN'S DISEASE; PARKINSON DISEASES | ELI LILLY AND COMPANY | 2001-04-03 | — | — | US | disclosed |
| EP-1003495-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999004778-A1 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012848-A1 | Pharmaceutical compounds | CHRM5, CHRM4, CHRM3 | MEN1 1772/4885NPC1 896/4885RAB9A 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.